Managing IBD in patients with CKD requires an individualized, stage-adjusted dosing strategy with vigilant renal monitoring, particularly in those with more advanced stages of renal disease.
Most inflammatory bowel disease therapies — particularly biologic agents — appear safe in patients with chronic kidney disease ; however, caution is required with certain conventional therapies, including immunomodulators and aminosalicylates, as well as with JAK inhibitors.
From 4% to 23% of patients with IBD also have renal disease, which can affect how the body processes medications; however, little data is available to guide physicians in choosing safe and effective IBD treatments for patients with advanced CKD. Researchers conducted a review of studies about IBD treatments in the setting of CKD by searching MEDLINE and EMBASE through March 31, 2025, using relevant keywords. IBD treatments evaluated were corticosteroids, aminosalicylates, immunomodulators , calcineurin inhibitors, biologics , integrin receptors, and interleukins), and small molecules .Corticosteroids in advanced kidney disease, including in patients requiring dialysis, do not require dosage adjustment. Budesonide is preferred over prednisolone, and corticosteroids are typically administered at the lowest effective dose for the shortest duration. Mesalazine, an aminosalicylate, can trigger acute interstitial nephritis; the immunomodulator methotrexate, even at 2-4 mg/wk, may cause irreversible renal decline, profound myelosuppression, and higher mortality in patients with end-stage kidney disease on hemodialysis; and calcineurin inhibitors can be nephrotoxic by reducing renal blood flow and glomerular filtration rate. Monoclonal antibodies, including anti-TNF, anti-integrin, and anti-interleukin 12/23 therapies, demonstrated safety in renal insufficiency and hemodialysis. For JAK inhibitors and thiopurines, dose adjustments were recommended in advanced renal disease, whereas S1P receptor modulators could be used in CKD without any dose adjustments.“Selecting appropriate therapeutics for managing IBD in patients with CKD necessitates a tailored approach, emphasizing diligent surveillance of renal function to optimize treatment efficacy and minimize renal compromise. Dose adjustments of IBD therapeutics are not required for patients with stage I or II CKD. Depending on specific drug metabolism and renal excretion, dose adjustments may be required at more advanced-stage CKD,” the authors wrote.The authors received no specific funding for this work. Two authors disclosed receiving advisory fees and serving as speakers for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Chronic Kidney Failure Chronic Kidney Disease CKD Chronic Kidney Disease (CKD) Renal Failure Renal Insufficiency Kidney Insufficiency Kidney Failure Renal Impairment Renal Disease Kidney Disease Kidney Disorder Renal Disorder Nephropathy Inflammatory Bowel Disease IBD Inflammatory Bowel Disease (IBD) Biologic Therapy Biologics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Fruits And Veggies Protective Against IBD, Study SaysA healthy plant-based diet might protect people from inflammatory bowel diseases, a new study says.
Read more »
ACG Refreshes Preventive Care in IBD GuidanceThe update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer, depression and anxiety, and the importance of quitting smoking.
Read more »
Bitcoin Bears Urge Caution as BTC Price Tops $122K: Crypto Daybook AmericasThe day ahead in crypto: July 14, 2025
Read more »
Mild and Moderate Infections Common in IBD, Rates Vary by Choice of TreatmentMild and moderate infections are common among patients with inflammatory bowel disease, with women having higher incidence rates than men.
Read more »
Technology Provides Aid in the Fight Against Workplace ViolenceBluetooth tools can send help exactly where it’s needed, when it’s needed.
Read more »
Sleep Changes in IBD Could Signal Inflammation, FlareupsChanges in sleep metrics detected with wearable technology could serve as an inflammation marker and potentially predict IBD flareups, regardless of symptoms.
Read more »